1. Home
  2. SB vs GERN Comparison

SB vs GERN Comparison

Compare SB & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safe Bulkers Inc ($0.001 par value)

SB

Safe Bulkers Inc ($0.001 par value)

SELL

Current Price

$7.82

Market Cap

971.0M

ML Signal

SELL

Logo Geron Corporation

GERN

Geron Corporation

SELL

Current Price

$1.17

Market Cap

1.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SB
GERN
Founded
2007
1990
Country
Monaco
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
971.0M
1.0B
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
SB
GERN
Price
$7.82
$1.17
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
★ $9.50
$4.25
AVG Volume (30 Days)
1.3M
★ 6.8M
Earning Date
11-24-2026
11-04-2026
Dividend Yield
★ 2.99%
N/A
EPS Growth
N/A
★ 51.85
EPS
★ N/A
N/A
Revenue
N/A
★ $1,065,000.00
Revenue This Year
$16.80
$28.49
Revenue Next Year
N/A
$44.73
P/E Ratio
$16.77
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$4.23
$1.04
52 Week High
$9.31
$2.01

Technical Indicators

Market Signals
Indicator
SB
GERN
Relative Strength Index (RSI) 39.51 36.90
Support Level $6.20 $1.08
Resistance Level $8.05 $1.26
Average True Range (ATR) 0.28 0.04
MACD -0.09 0.01
Stochastic Oscillator 3.69 15.00

Price Performance

Historical Comparison
SB
GERN

About SB Safe Bulkers Inc ($0.001 par value)

Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain, and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services. The company generates almost all of its revenue from Time Charters.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: